Profile data is unavailable for this security.
About the company
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
- Revenue in SEK (TTM)222.27m
- Net income in SEK-529.25m
- Incorporated2007
- Employees125.00
- LocationHansa Biopharma ABScheelevagen 22,P.O. Box 785LUND 220 07SwedenSWE
- Phone+46 46165670
- Fax+46 46127775
- Websitehttps://www.hansabiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diamyd Medical AB | 348.00k | -182.46m | 2.28bn | 41.00 | -- | 10.09 | -- | 6,545.81 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Transgene SA | 76.66m | -389.50m | 2.47bn | 147.00 | -- | -- | -- | 32.19 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Cellectis SA | 736.66m | -315.47m | 2.52bn | 224.00 | -- | 2.82 | -- | 3.43 | -0.297 | -0.297 | 0.6916 | 1.17 | 0.2234 | -- | 8.58 | 310,550.20 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Eurobio Scientific SA | 1.72bn | 25.01m | 2.61bn | 380.00 | 102.51 | 1.33 | 13.83 | 1.52 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Oryzon Genomics SA | 0.00 | -28.08m | 2.66bn | 47.00 | -- | 2.09 | -- | -- | -0.0406 | -0.0406 | 0.00 | 1.51 | 0.00 | 95.26 | -- | 0.00 | -2.08 | -3.91 | -2.37 | -4.48 | -- | -- | -- | -- | 2.13 | -8.64 | 0.0725 | -- | -- | -- | -9.32 | -- | -4.26 | -- |
| Vicore Pharma Holding AB | 8.50m | -424.45m | 3.00bn | 36.00 | -- | 3.13 | -- | 352.36 | -1.85 | -1.85 | 0.0371 | 3.40 | 0.0134 | -- | 2.04 | 293,137.90 | -66.65 | -49.13 | -71.78 | -54.58 | -- | -- | -4,992.90 | -1,107.81 | -- | -35.34 | 0.00 | -- | -- | -- | 45.77 | -- | -- | -- |
| Avacta Group Plc | -135.09m | -402.99m | 3.11bn | 151.00 | -- | 1,585.70 | -- | -- | -0.0891 | -0.1579 | -0.0298 | 0.0004 | -0.1872 | -- | -- | -73,456.95 | -55.83 | -43.48 | -129.38 | -78.27 | -- | 63.54 | -- | -781.44 | 0.7883 | -0.4837 | 0.993 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Saniona AB | 743.21m | 573.47m | 3.49bn | 31.00 | 5.50 | 5.07 | 6.02 | 4.70 | 4.60 | 4.60 | 5.98 | 5.00 | 1.75 | -- | 121.92 | 33,782,040.00 | 135.23 | -38.47 | 170.81 | -45.71 | 90.13 | -55.15 | 77.16 | -156.43 | -- | -- | 0.0004 | -- | 1,887.36 | 115.50 | 296.96 | -- | -48.69 | -- |
| Genfit SA | 480.88m | -410.46m | 3.78bn | 188.00 | -- | 6.79 | -- | 7.86 | -0.7737 | -0.7737 | 0.9083 | 1.05 | 0.2207 | 519.75 | 0.9236 | 252,277.80 | -18.84 | -7.73 | -23.25 | -9.79 | 95.42 | 95.68 | -85.35 | -37.15 | 3.74 | -10.87 | 0.1223 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Puretech Health PLC | 57.03m | 452.23m | 3.78bn | 56.00 | 8.47 | 1.12 | 12.00 | 66.34 | 0.1518 | 0.1518 | 0.0194 | 1.15 | 0.0113 | -- | 2.81 | 83,620.53 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Hansa Biopharma AB | 222.27m | -529.25m | 4.07bn | 125.00 | -- | -- | -- | 18.31 | -6.44 | -6.44 | 2.73 | -0.8268 | 0.226 | 19.12 | 2.24 | 1,778,120.00 | -53.80 | -57.18 | -81.36 | -73.22 | 62.41 | 60.32 | -238.12 | -464.70 | 1.92 | -- | 1.10 | -- | 29.74 | 105.28 | 34.44 | -- | -- | -- |
| Formycon AG | 548.32m | -1.80bn | 4.45bn | 245.00 | -- | 1.03 | -- | 8.12 | -9.60 | -9.60 | 2.93 | 23.12 | 0.0613 | 31.72 | 1.91 | 207,112.00 | -20.09 | -1.47 | -21.17 | -1.58 | -0.9927 | 25.54 | -327.88 | -13.00 | 1.51 | -1.27 | 0.0244 | -- | -10.32 | 15.48 | -265.81 | -- | 96.87 | -- |
| Newron Pharmaceuticals SpA | 633.84m | 268.09m | 4.62bn | 22.00 | 15.98 | 275.10 | 17.11 | 7.29 | 1.24 | 1.24 | 2.83 | 0.0722 | 1.39 | -- | 11.69 | 2,478,738.00 | 58.67 | -23.70 | 123.93 | -32.05 | 98.17 | 97.14 | 42.30 | -69.33 | -- | 8.56 | 0.9708 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
Data as of Feb 13 2026. Currency figures normalised to Hansa Biopharma AB's reporting currency: Swedish Krona SEK
39.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Oct 2025 | 17.51m | 17.21% |
| Polar Capital LLPas of 31 Oct 2025 | 11.06m | 10.87% |
| Braidwell LPas of 28 Aug 2025 | 4.13m | 4.06% |
| Fj�rde AP-fondenas of 31 Oct 2025 | 2.57m | 2.52% |
| Handelsbanken Fonder ABas of 31 Oct 2025 | 1.76m | 1.73% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 1.18m | 1.16% |
| Sphera Funds Management Ltd.as of 31 Dec 2024 | 1.11m | 1.09% |
| SEB Funds ABas of 31 Dec 2025 | 670.83k | 0.66% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 336.78k | 0.33% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 285.73k | 0.28% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
